Shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) have received a consensus rating of “Buy” from the nine ratings firms that are presently covering the firm. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $41.45.

A number of analysts have issued reports on PTLA shares. Cowen and Company set a $40.00 price target on shares of Portola Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, February 8th. Oppenheimer Holdings Inc. set a $28.00 price target on shares of Portola Pharmaceuticals and gave the company a “hold” rating in a report on Wednesday, February 8th. Citigroup Inc set a $39.00 price target on shares of Portola Pharmaceuticals and gave the company a “buy” rating in a report on Friday, February 17th. CIBC upgraded shares of Portola Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Friday, February 24th. Finally, Vetr downgraded shares of Portola Pharmaceuticals from a “buy” rating to a “sell” rating and set a $36.36 price target on the stock. in a report on Wednesday, March 1st.

Shares of Portola Pharmaceuticals (NASDAQ:PTLA) traded down 0.75% on Monday, reaching $38.59. 263,935 shares of the company traded hands. The stock has a 50-day moving average price of $39.07 and a 200 day moving average price of $29.72. The firm’s market capitalization is $2.20 billion. Portola Pharmaceuticals has a 1-year low of $15.68 and a 1-year high of $42.74.

Portola Pharmaceuticals (NASDAQ:PTLA) last announced its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.74) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.20) by $0.46. The firm had revenue of $5.12 million for the quarter, compared to the consensus estimate of $4.21 million. Portola Pharmaceuticals had a negative net margin of 1,072.67% and a negative return on equity of 82.19%. The company’s revenue was down 37.9% on a year-over-year basis. During the same period last year, the firm earned ($1.15) EPS. Analysts anticipate that Portola Pharmaceuticals will post ($4.44) EPS for the current fiscal year.

In other Portola Pharmaceuticals news, Director Charles J. Homcy sold 50,000 shares of Portola Pharmaceuticals stock in a transaction on Wednesday, March 15th. The shares were sold at an average price of $40.06, for a total value of $2,003,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO William Lis sold 6,750 shares of Portola Pharmaceuticals stock in a transaction on Tuesday, April 11th. The shares were sold at an average price of $36.06, for a total transaction of $243,405.00. Following the completion of the sale, the chief executive officer now owns 4,730 shares in the company, valued at $170,563.80. The disclosure for this sale can be found here. Over the last quarter, insiders sold 68,082 shares of company stock worth $2,696,566. 4.90% of the stock is currently owned by insiders.

Hedge funds have recently made changes to their positions in the stock. Marcus Capital LLC increased its stake in Portola Pharmaceuticals by 8.7% in the third quarter. Marcus Capital LLC now owns 81,700 shares of the biopharmaceutical company’s stock worth $1,855,000 after buying an additional 6,550 shares during the period. BlackRock Fund Advisors increased its stake in Portola Pharmaceuticals by 5.6% in the third quarter. BlackRock Fund Advisors now owns 2,058,331 shares of the biopharmaceutical company’s stock worth $46,745,000 after buying an additional 109,789 shares during the period. Teachers Advisors LLC increased its stake in Portola Pharmaceuticals by 3.9% in the third quarter. Teachers Advisors LLC now owns 80,029 shares of the biopharmaceutical company’s stock worth $1,817,000 after buying an additional 3,030 shares during the period. TIAA CREF Investment Management LLC increased its stake in Portola Pharmaceuticals by 2.3% in the third quarter. TIAA CREF Investment Management LLC now owns 238,947 shares of the biopharmaceutical company’s stock worth $5,426,000 after buying an additional 5,370 shares during the period. Finally, BlackRock Institutional Trust Company N.A. increased its stake in Portola Pharmaceuticals by 3.8% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,402,266 shares of the biopharmaceutical company’s stock worth $31,845,000 after buying an additional 50,984 shares during the period. Institutional investors own 87.38% of the company’s stock.

WARNING: “Portola Pharmaceuticals Inc (PTLA) Receives Average Recommendation of “Buy” from Brokerages” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/05/22/portola-pharmaceuticals-inc-ptla-receives-average-recommendation-of-buy-from-brokerages.html.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

12 Month Chart for NASDAQ:PTLA

Receive News & Ratings for Portola Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.